These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26084446)

  • 21. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
    Pece A; Milani P; Monteleone C; Trombetta CJ; De Crecchio G; Fasolino G; Matranga D; Cillino S; Vadalà M
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1867-72. PubMed ID: 25500986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CLINICAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB VERSUS PHOTODYNAMIC THERAPY WITH OR WITHOUT BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION: A 7-Year Follow-up Study.
    Kang EC; Seo JG; Kim BR; Koh HJ
    Retina; 2017 Sep; 37(9):1775-1783. PubMed ID: 27997511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal Bevacizumab for Nonsubfoveal Choroidal Neovascularization Associated With Angioid Streaks: 3-Year Follow-up Study.
    Iacono P; Battaglia Parodi M; La Spina C; Bandello F
    Am J Ophthalmol; 2016 May; 165():174-8. PubMed ID: 27013066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D; Gad MA; Enam KM
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization.
    Traversi C; Nuti E; Marigliani D; Cevenini G; Balestrazzi A; Martone G; Caporossi T; Tosi GM
    Graefes Arch Clin Exp Ophthalmol; 2015 Apr; 253(4):511-7. PubMed ID: 25016478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
    Kasahara K; Moriyama M; Morohoshi K; Yoshida T; Simada N; Nagaoka N; Yokoi T; Shinohara K; Kaneko Y; Suga M; Ohno-Matsui K
    Retina; 2017 Jun; 37(6):1055-1064. PubMed ID: 27755380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
    Arias L; Planas N; Prades S; Caminal JM; Rubio M; Pujol O; Roca G
    Br J Ophthalmol; 2008 Aug; 92(8):1035-9. PubMed ID: 18653595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
    Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
    Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
    Chen C; Yan M; Huang Z; Song YP
    Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.
    Oishi A; Yamashiro K; Tsujikawa A; Ooto S; Tamura H; Nakata I; Miyake M; Yoshimura N
    Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):1-7. PubMed ID: 22527326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
    Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; Català J; Garcia-Bru P; Arruga J
    Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection.
    Wang J; Kang Z
    Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1717-23. PubMed ID: 23007232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
    Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
    Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.